Compare XOS & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOS | CLGN |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 18.4M |
| IPO Year | N/A | N/A |
| Metric | XOS | CLGN |
|---|---|---|
| Price | $2.15 | $1.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 43.2K | 40.1K |
| Earning Date | 11-13-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,246,000.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | $25.72 | $85.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 280.77 |
| 52 Week Low | $1.74 | $1.30 |
| 52 Week High | $9.15 | $4.98 |
| Indicator | XOS | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 37.10 |
| Support Level | $1.74 | $1.37 |
| Resistance Level | $2.15 | $1.51 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 89.04 | 53.78 |
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.